Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer

doi:10.1016/j.euo.2025.10.010

Return

Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer

2025-11-04

Elizabeth A. Harrington

Jinyu Kang

Noel W. Clarke

DOI：10.1016/j.euo.2025.10.010

Original

Save

View PDF

Abstract

En 中文

PROpel (NCT03732820) demonstrated a statistically significant radiographic progression-free survival (rPFS) benefit with olaparib plus abiraterone (Ola + Abi) versus placebo plus abiraterone (P + Abi) in first-line metastatic castration-resistant prostate cancer (mCRPC). We conducted exploratory analyses in the intention-to-treat (ITT) population and subgroups stratified by homologous recombination repair gene mutation (HRRm) and BRCA1 and/or BRCA2 mutation (BRCAm) status.

Keywords:

Abiraterone

Metastatic castration-resistant prostate cancer

Objective response

Olaparib

PARP inhibitor

Prostate-specific antigen

Survival

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.